Ramachandran Murali - Jan 1, 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Role
VP of Research and Development
Signature
/s/ Ramachandran Murali
Stock symbol
KAPA
Transactions as of
Jan 1, 2025
Transactions value $
$0
Form type
4
Date filed
2/24/2025, 06:52 PM
Previous filing
Nov 25, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KAPA COMMON STOCK Award $0 +14K +10.52% $0.00 147K Jan 1, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof.
F2 Consists of (1) 137,724 shares of common stock and (2) 9,333 RSUs which remain subject to vesting.